Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  1998-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1046/J.1365-2125.1998.00722.XPMID 9663812PMCID PMC1873652
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man

  2004cited by this paper
• SOME QUANTITATIVE USES OF DRUG ANTAGONISTS

  1997cited by this paper
• Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.

  1997cited by this paper
• Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men

  1996cited by this paper
• Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine.

  1995cited by this paper
• TCV‐116: A New Angiotensin II Type‐1 Receptor Antagonist

  1994cited by this paper
• Widespread tissue distribution of human chymase.

  1994cited by this paper
• Angiotensin II antagonists DuP 753 and TCV 116.

  1994cited by this paper
• Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl

  1993cited by this paper
• Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension.

  1993cited by this paper
• Cough and inhibition of the renin-angiotensin system.

  1993cited by this paper
• Angiotensin II receptors and angiotensin II receptor antagonists.

  1993cited by this paper
• Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy

  1992cited by this paper
• Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart.

  1991cited by this paper
• Renin system blockade as a therapeutic strategy. Past, present, and future.

  1991cited by this paper
• Renin System Blockade as a Therapeutic Strategy

  1991cited by this paper
• Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart.

  1990cited by this paper
• The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.

  1989cited by this paper
• Brain angiotensin: pathways and pharmacology

  1988cited by this paper
• Beta adrenoceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans. Evaluation with Schild-plots.

  1988cited by this paper
• A method for estimating the potency of angiotensin-converting enzyme inhibitors in man.

  1987cited by this paper
• Hemodynamic Responses to Angiotensin I in Normal Volunteers and the Antagonism by the Angiotensin‐Converting Enzyme Inhibitor Cilazapril

  1987cited by this paper
• Inhibition of angiotensin‐I response by cilazapril and its time course in normal volunteers *

  1987cited by this paper
• Theories of drug antagonism.

  1957cited by this paper
• The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves

  year unknowncited by this paper

• Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients

  2021cites this paper
• Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

  2016cites this paper
• Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

  2014cites this paper
• Binding kinetics differentiates functional antagonism of orexin‐2 receptor ligands

  2014cites this paper
• A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists

  2013influential citation
• An Explicit Review on Quantitative Estimation of Candesartan Cilexetil Employing Various Analytical Techniques

  2013cites this paper
• Candesartan Cilexetil

  2012cites this paper
• Specific and Stability Indicating Assay Method of Cadesartan Cilexetil in Presence of Process and Degradation Impurities

  2012cites this paper
• The CHARM program: the effects of candesartan for the management of patients with chronic heart failure

  2009cites this paper
• Candesartan for the management of heart failure: more than an alternative

  2006cites this paper
• Current and future uses of candesartan in the treatment of heart failure.

  2006cites this paper
• Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans

  2004cites this paper
• Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology.

  2003cites this paper
• Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers

  2002cites this paper
• The Relationships Between Dose and Antihypertensive Effect of Four AT 1 -receptor Blockers. Differences in Potency and Efficacy

  2002cites this paper
• Clinical Pharmacokinetics of Candesartan

  2002cites this paper
• Pharmacodynamic Studies on the Angiotensin II Type 1 Antagonists Irbesartan and Candesartan Based on Angiotensin II Dose Response in Humans

  2002cites this paper
• Rezeptorkinetik von AT1-Rezeptorantagonisten: Kompetitiver und pseudonichtkompetitiver Bindungstyp

  2001cites this paper
• [Pharmacologic basics: the effect of AT1 receptor antagonists].

  2001cites this paper
• Pharmacological Differences among Angiotensin II Receptor Antagonists

  2001cites this paper
• Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge

  2001cites this paper
• Do saw palmetto extracts block humanα1‐adrenoceptor subtypes in vivo?

  2001cites this paper
• Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo?

  2001cites this paper
• The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man

  2000influential citation
• Comparative Pharmacodynamics and Pharmacokinetics of Candesartan and Losartan in Man

  2000cites this paper
• Blocking the tissue renin-angiotensin system: the future cornerstone of therapy

  2000cites this paper
• Candesartan Cilexetil: An Angiotensin II Receptor Blocker

  1999cites this paper
• Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.

  1999cites this paper
• Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.

  1999cites this paper
• Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.

  1999cites this paper
• Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay

  1999cites this paper
• Angiotensin II Receptor Blockade in Normotensive Subjects A Direct Comparison of Three AT 1 Receptor Antagonists

  1999cites this paper
• Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.

  1999cites this paper